Euroimmun Medical Diagnostics: Powering High-Quality Development of Autoimmune Disease Diagnosis in China

This is an era of industry ascent, as well as an era filled with competition.

Driven by the accelerating aging population in China, increased capital investment, and heightened public health awareness, the Chinese in vitro diagnosis (hereinafter referred to as “IVD”) market has experienced explosive growth.

According to statistics, the size of China's IVD market grew from RMB 45 billion in 2016 to RMB 124.3 billion in 2021, and is expected to continue its growth trajectory, reaching RMB 146 billion in 2022 and approaching RMB 200 billion by 2024 (Note ①).

In the IVD market, the autoimmune disease diagnostics segment—a niche within this broader market—has achieved a compound annual growth rate (CAGR) exceeding 10%, indicating that the accelerated growth of autoimmune disease diagnostics has become a key driver for the development of China’s IVD market.

Having been firmly established in the Chinese market for 15 years, EUROIMMUN Medical (Note ②) is currently a leading company in China’s autoimmune disease diagnostics market. Leveraging its technological and market capabilities, the company drives industry development. To date, EUROIMMUN Medical has received numerous honors and recognitions, including National High-Tech Enterprise, Zhongguancun High-Tech Enterprise, Beijing “Specialized, Refined, Differential, and Innovative” Enterprise, and Beijing Intellectual Property Pilot Unit.

On March 31 this year, the 17th National Congress of Laboratory Medicine of the Chinese Medical Association (Changsha), a two-day event hosted by the Chinese Medical Association and its Branch of Laboratory Medicine, and organized by the Hunan Medical Association, was grandly convened. The congress focused on the latest research findings and development trends in clinical laboratory testing and laboratory management, and facilitated exchanges and discussions on the new situations and challenges facing the field of laboratory medicine.

During the conference, Euroimmun Diagnostics, as the pioneer and leader ushering in the era of standardization for autoantibody testing in China, grandly held the new product launch event themed “Standing at the Heights, Living Towards the Light,” announcing the official market launch of its “Fully Automated Chemiluminescence Immunoassay Platform.” Distinguished attendees included Professor Wang Chuanxin, Chairman of the Laboratory Medicine Branch of the Chinese Medical Association; Professor Pan Baishen, Editor-in-Chief of the Chinese Journal of Laboratory Medicine; Professor Zhong Renqian, former Director of the Department of Experimental Diagnosis and the PLA Institute of Immunodiagnosis at Shanghai Changzheng Hospital; Mr. Li Chuan, CEO of Euroimmun Diagnostics, Executive Dean and Founder of Yiwei Academy; Director Gan Ling from the Editorial Office of the Chinese Journal of Laboratory Medicine; Professor Zheng Lei, Director of the Department of Laboratory Medicine at Nanfang Hospital, Southern Medical University; Professor Yi Bin, Director of the Department of Laboratory Medicine at Xiangya Hospital, Central South University; Professor Ji Ling, Director of the Department of Laboratory Medicine at Peking University Shenzhen Hospital; along with other industry leaders, experts, and corporate representatives. The launch of Euroimmun’s chemiluminescence immunoassay platform heralds a new chapter in the diagnosis of autoimmune diseases.

 Ribbon-Cutting Ceremony at EUROIMMUN Medical Diagnostics New Product Launch Event

The National Academic Conference on Laboratory Medicine (Changsha) also featured forums such as “Challenges and Difficulties in Clinical Molecular Diagnostics,” the Mass Spectrometry Summit, “New Advances in Laboratory Diagnosis of Autoimmune Diseases,” and “Frontier Progress in Clinical Chemistry Biomarkers for Major Diseases.”

Wang Chuanxin, Chairman of the Chinese Society of Laboratory Medicine under the Chinese Medical Association, delivered the opening address at the conference. He stated that this event is the most prominent academic gathering in China’s field of laboratory medicine. Having taken place after three years of the pandemic, it holds significant meaning and far-reaching influence. He expressed his hope that the conference would fully showcase the latest research findings and development trends across various domains of clinical laboratory testing and laboratory management, facilitate extensive and thorough exchanges and discussions on the new situations and challenges facing laboratory medicine, and continuously improve the diagnostic and therapeutic capabilities of the discipline. He looked forward to working with all attendees to promote substantial development and prosperity in laboratory medicine, thereby contributing to the advancement of the Healthy China initiative.

 Wang Chuanxin Delivers Address at Euroimmun’s New Product Launch Event

As a global leader in the diagnosis of autoimmune diseases, allergen testing, and infectious disease detection, EUROIMMUN Medical Diagnostics operates in 17 countries and regions, with its products benefiting more than 150 countries and tens of thousands of laboratories worldwide. Notably, sales in the Chinese market account for 50% of EUROIMMUN’s global revenue, making a significant contribution to the company’s worldwide growth.

“The past two decades have witnessed the rapid rise of China’s autoimmune diagnostics industry and the vigorous development of in vitro diagnostic (IVD) technologies. Through continuous technological innovation, EUROIMMUN has achieved comprehensive methodological coverage in the diagnosis of autoimmune diseases, enabling it to provide products and services tailored to the needs of healthcare institutions at various levels. This helps patients obtain precise diagnoses at an early stage through autoantibody testing. Moving forward alongside the industry, EUROIMMUN has participated in and witnessed the growth, development, and prosperity of the medical diagnostics sector.”In an interview with the media, Li Chuan, CEO of EUROIMMUN Medical Diagnostics, stated that China’s laboratory medicine technology will usher in a period of rapid market-oriented, informatized, and intelligent development. EUROIMMUN will continue to strengthen its diagnostic technology capabilities, constantly explore innovative health service models, benefit millions of Chinese patients with autoimmune diseases through cutting-edge diagnostic technologies and advanced diagnostic products, lead the new development of China’s autoimmune diagnostics ecosystem, aim high to secure future success, and contribute to the Healthy China initiative.

Li Chuan, CEO, Delivers Remarks at the Launch Event for Euroimmun’s New Diagnostic Products

Notably, the new chemiluminescence-based product launched at this press conference—the EUROIMMUN ZETA C21 Fully Automated Chemiluminescence Immunoassay Platform—made its global public debut. This product enhances and complements EUROIMMUN’s multi-methodology testing platform. When used in conjunction with EUROIMMUN’s chemiluminescence reagents, it provides clinicians with more comprehensive and precise diagnostic evidence, marking a significant step in EUROIMMUN’s future strategy for intelligent laboratory solutions. The new system is applied to the diagnosis, disease assessment, and treatment monitoring of autoimmune diseases—including systemic lupus erythematosus, systemic sclerosis, systemic vasculitis, inflammatory myopathies, autoimmune kidney diseases, and autoimmune liver diseases—as well as infectious diseases. Furthermore, independently developed by EUROIMMUN’s Chinese R&D team, this product represents a key implementation of EUROIMMUN’s “Intelligent Manufacturing in China + Deep Integration” strategy.

 EUROIMMUN Medical Diagnostics New Product Launch

Autoimmune liver disease, autoimmune encephalitis, and idiopathic membranous nephropathy were once regarded as “idiopathic” “refractory diseases” or “rare diseases.” However, with advances in diagnostic technologies, these conditions have been identified as “autoimmune diseases.” Data indicate that approximately 7.6% to 9.4% of the global population suffers from various autoimmune diseases, while the number of patients in China has reached as high as 50 million.

Since 2008, EUROIMMUN Medizin has been deeply committed to the field of medical diagnostics. By leveraging its leading standardized indirect immunofluorescence test (IIFT) platform, the company has facilitated the widespread adoption of autoantibody testing in hospitals at all levels, ensuring more stable assay performance, standardized quality control, and greater accuracy of results. The diverse patterns of “green fluorescence” observed under the microscope have become a critical basis for diagnosing autoimmune diseases, significantly advancing the diagnosis and treatment of these conditions in China.

Encouragingly, Euroimmun’s green fluorescence technology is now widely applied in the diagnosis of infectious diseases, in addition to autoimmune disorders. It plays a unique role that other methodologies cannot achieve and has gained high recognition from hospitals at all levels.

Moreover, it is the responsibility and mission of healthcare enterprises to address diagnostic challenges through technological innovation, thereby benefiting more patients.

According to Li Chuan, Euroimmun has long been dedicated to technological innovation and development. By engaging in extensive and close scientific collaborations with numerous domestic and international medical institutions and research organizations, the company has accumulated substantial clinical laboratory data. It aims to identify more valuable biomarkers to serve as diagnostic criteria, thereby further expanding the boundaries of knowledge on autoimmune diseases. This effort is intended to continuously drive industry-wide upgrading and development, ultimately benefiting the vast number of autoimmune disease patients in China.

China has now become the world’s second-largest healthcare market. Euroimmun China has evolved into a comprehensive enterprise integrating R&D, manufacturing, sales, marketing, and services. It holds multiple exclusive patented technologies and several globally unique products. To date, it has established collaborations with nearly 2,000 medical institutions across China, providing comprehensive diagnostic and treatment services to 50 million rheumatism patients nationwide. Industry data show that, leveraging a strategic layout aligned with Chinese market demands and a modern corporate management system, Euroimmun China has achieved sustained, stable, and rapid sales growth, with its market share consistently accounting for over 80% of China’s autoimmune disease diagnostics market.

Currently, safeguarding public health has become one of the nation’s top strategic priorities.

Li Chuan stated that, in the face of unprecedented opportunities in the health market, expanding into primary care and regional markets is one of Euroimmun’s three major strategies. In addition, Euroimmun Medical has also implemented a user growth strategy across two key dimensions.

The first dimension involves innovation and enrichment in products and technology. Currently, EUROIMMUN Medical has established a product portfolio in China, with laboratory diagnostic products for autoimmune, infectious, and allergic diseases, along with supporting automated instruments, laboratory testing services, and molecular diagnostics as core offerings. It is also equipped with its own R&D technical team, providing guaranteed talent support for the continuous iteration and enrichment of its products.

The second dimension is that pursuing technological innovation is an inherent tradition within EUROIMMUN Medical. “We hope that every employee within the company will regard the pursuit of advanced technological innovation and the quest for excellence as a core belief. Furthermore, EUROIMMUN Medical will continue to strengthen its AI research capabilities in China. For instance, in the field of indirect immunofluorescence testing, AI technology will be leveraged to automate result interpretation, continuously enhance testing standardization, and maximize the intelligent automation of routine diagnostics,” stated Li Chuan.

Guided by the corporate mission of “helping China’s medical laboratory industry move toward a brighter future,” Li Chuan further proposed that EUROIMMUN Medical should empower hospitals. From the perspective of products and service endpoints, the primary endpoint for disease diagnosis is the clinical laboratory departments of major hospitals across China.

“But if we take a step forward, the laboratory department actually serves physicians across various clinical departments,” said Li Chuan. He stated that in the future, Euroimmun will not only sell products to the laboratory department but also help laboratory physicians conduct better market education, enabling clinicians to gain a deeper understanding of test parameters.

“A Tower of Nine Stories Begins with a Pile of Earth.” At the Starting Point of the New Era, Euroimmun’s New Blueprint in China May Already Be Unveiled. By Continuously Advancing Diagnostic Technologies, Exploring Innovative Health Service Models, and Strengthening Its Integrated “R&D–Production–Sales–Service” Value Chain, Euroimmun Is Driving Industry-Wide Upgrading and Development. Through Cutting-Edge Diagnostic Technologies and Advanced Diagnostic Products, It Aims to Benefit Millions of Patients with Autoimmune Diseases in China and Contribute to the Nation’s Healthcare Endeavors.

Note ① Data sourced from Frost & Sullivan and China Business Industry Research Institute

Note ② In this press release, “Euroimmun China” and “Euroimmun Medicine” are both abbreviations for Euroimmun Medical Diagnostics (China) Co., Ltd.

EUROIMMUN Medical Diagnostics (China) Co., Ltd. http://www.oumeng.com.cn

As a high-tech enterprise focused on medical diagnostics, EUROIMMUN has always adhered to its corporate mission of “Technological Innovation Creates Excellence; EUROIMMUN Diagnostics Promotes Human Health.” By gaining deep insights into market demands and leveraging high-quality in vitro diagnostic products and services, we provide comprehensive laboratory solutions for customers in China and the Asia-Pacific region.

Euroimmun has accumulated profound expertise and technological advantages in the field of autoimmune diseases. Its diagnostic products are widely used in the diagnosis of autoimmune diseases, infectious diseases, allergic diseases, and neuropsychiatric disorders. In its process of localization and internationalization, Euroimmun has established a comprehensive production system for reagents and automated instruments, forming a “dual-core” technology platform based on serological diagnostics and molecular diagnostics. Through innovative testing technologies, it continuously enhances the precision and reliability of disease diagnosis. Today, Euroimmun has developed into a national high-tech enterprise integrating R&D, production, marketing, distribution, and services, with its products and technical services serving healthcare institutions and medical laboratories across the Asia-Pacific region.